Aromatase deficiency in men: A clinical perspective

Nature Reviews Endocrinology

Volumn 5, Issue 10, 2009, Pages 559-568

  Rochira, Vincenzo ^a   Carani, Cesare ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; BIOCHEMICAL MARKER; CALCIUM; ESTRADIOL; LUTEINIZING HORMONE; RALOXIFENE; VITAMIN D;

AROMATASE DEFICIENCY; BONE MATURATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENZYME DEFICIENCY; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FOLLOW UP; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MEDICAL PRACTICE; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

AROMATASE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; HUMANS; LUTEINIZING HORMONE; MALE; TESTOSTERONE;

EID: 70349570680     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.176     Document Type: Review

References (70)

1. Faustini-Fustini, M., Rochira, V. & Carani, C. Oestrogen deficiency in men: where are we today? Eur. J. Endocrinol. 140, 111-129 (1999).
2. Grumbach, M. M. & Auchus, R. J. Estrogen: consequences and implications of human mutations in synthesis and action. J. Clin. Endocrinol. Metab. 84, 4677-4694 (1999).
3. Deladöey, J. et al. Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J. Clin. Endocrinol. Metab. 84, 4050-4054 (1999).
4. Bouillon, R., Bex, M., Vanderschueren, D. & Boonen, s. Estrogens are essential for male pubertal periosteal bone expansion. J. Clin. Endocrinol. Metab. 89, 6025-6029 (2004).
5. Morishima, A., Grumbach, M. M., simpson, E. R., Fisher, C. & Qin, K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80, 3689-3698 (1995).
6. Carani, C. et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 337, 91-95 (1997).
7. Herrmann, B. L. et al. Impact of estrogen replacement therapy in a male with congenital aromatase decifiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 87, 5476-5484 (2002).
8. Pura, M., Mittre, H., Carreau, s. & Kottler, M. L. Clinical findings in an adult man with a novel mutation in the aromatase gene [abstract]. In Program of the 85th Annual Meeting of the Endocrine Society 243 (The Endocrine society, Philadelphia, 2003).
9. Maffei, L. et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J. Clin. Endocrinol. Metab. 89, 61-70 (2004).
10. Maffei, L. et al. A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital estrogen deficiency, adiposity and the metabolic syndrome. Clin. Endocrinol. (Oxf.) 67, 218-224 (2007).
11. Lanfranco, F. et al. A novel mutation in the human aromatase gene: Insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment. Bone 43, 628-635 (2008).
12. Rochira, V., Balestrieri, A., Madeo, B., spaggiari, A. & Carani, C. Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol. Cell. Endocrinol. 193, 19-28 (2002).
13. smith, E. P. et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331, 1056-1061 (1994).
14. Deroo, B. J. & Korach, K. s. Estrogen receptors and human disease. J. Clin. Invest. 116, 561-570 (2006).
15. Rochira, V. et al. Estrogens in males: what have we learned in the last 10 years? Asian J. Androl. 7, 3-20 (2005).
16. Balestrieri, A., Faustini-Fustini, M., Rochira, V. & Carani, C. Clinical implications and management of estrogen deficiency in the male. Clin. Endocrinol. (Oxf.) 54, 431-432 (2001).
17. Rochira, V., Balestrieri, A., Faustini-Fustini, M. & Carani, C. Role of estrogen on bone in the human male: insights from the natural models of congenital estrogen deficiency. Mol. Cell. Endocrinol. 178, 215-220 (2001).
18. Zirilli, L., Rochira, V., Diazzi, C., Caffagni, G. & Carani, C. Human models of aromatase deficiency. J. Steroid Biochem. Mol. Biol. 109, 212-218 (2008).
19. Lee, P. A. & witchel, s. F. The influence of estrogen on growth. Curr. Opin. Pediatr. 9, 431-436 (1997).
20. Jones, M. E. et al. Recognizing rare disorders: aromatase deficiency. Nat. Clin. Pract. Endocrinol. Metab. 3, 414-421 (2007).
21. Mullis, P. E. et al. Aromatase deficiency in a female who is compound heterozygote for new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicistic ovaries, and bone densitometry in childhood. J. Clin. Endocrinol. Metab. 82, 1739-1745 (1997).
22. Belgorosky, A. et al. Hypotalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene. J. Clin. Endocrinol. Metab. 88, 5127-5131 (2003).
23. Lin, L. et al. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J. Clin. Endocrinol. Metab. 92, 982-990 (2007).
24. Manganiello, P. D., Adams, L. V., Harris, R. D. & Ornvold, K. Virilization during pregnancy with spontaneous resolution postpartum: a case report and review of the English literature. Obstet. Gynecol. Surv. 50, 404-410 (1995).
25. Ogilvie, M., Davidson, J. s., Cuttance. P. & Milsom. s. severe maternal virilisation of benign etiology in two successive pregnancies. BJOG 112, 1443-1445 (2005).
26. scott, R. R. & Miller, w. L. Genetic and clinical features of p450 oxidoreductase deficiency. Horm. Res. 69, 266-275 (2008).
27. Fukami, M. et al. Cytochrome P450 Oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J. Clin. Endocrinol. Metab. 94, 1723-1731 (2009).
28. Costa-santos, M., Kater, C. E., Auchus, R. J. & Brazilian Congenital Adrenal Hyperplasia Multicenter study Group. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 89, 49-60 (2004).
29. Rosa, s. et al. P450c17 deficiency: clinical and molecular characterization of six patients. J. Clin. Endocrinol. Metab. 92, 1000-1007 (2007).
30. Finkelstein, J. s. et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med. 106, 354-361 (1987).
31. Nieschlag, E. & Behre, H. M. in Testosterone Action Deficiency Substitution 3rd edn (eds Nieschlag, E. & Bhere, H. M.) 375-403 (Cambridge University Press, Cambridge, UK, 2004).
32. Rochira, V. et al. Osteoporosis and male agerelated hypogonadism: role of sex steroids on bone (patho)physiology. Eur. J. Endocrinol. 154, 175-185 (2006).
33. Rodd, C., Jourdain, N. & Alini, M. Action of estradiol on epiphyseal growth plate chondrocytes. Calcif. Tissue Int. 75, 214-224 (2004).
34. Greulich, w. w. & Pyle, s. I. (eds) in Radiographic Atlas of Skeletal Development of the Hand and Wrist 2nd edn (stanford University Press, stanford, 1959).
35. Tanner, J. M., whitehouse, R. H., Marshall, w. A., Healy, M. J. R. & Goldstein, H. The Assessment of Skeletal Maturity and the Prediction of Adult Height (TW2 method) 2nd edn (Academic, London, 1983).
36. Bay, K., Andersson, A. M. & skakkebaek, N. E. Estradiol levels in prepubertal boys and girls- analytical challenges. Int. J. Androl. 27, 266-273 (2004).
37. santen, R. J. et al. superiority of gas chromatography/tandem mass spectrometry assay (GC/Ms/Ms) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72, 666-671 (2007).
38. Rochira, V., Faustini-Fustini, M., Balestrieri, A. & Carani, C. Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters. J. Clin. Endocrinol. Metab. 85, 1841-1845 (2000).
39. Rochira, V. et al. Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback. Eur. J. Endocrinol. 155, 513-522 (2006).
40. Rochira, V. et al. Oestradiol replacement treatment and glucose homeostasis in two men with congenital aromatase deficiency: evidence for a role of estradiol and sex steroids imbalance on insulin sensitivity in men. Diabet. Med. 24, 1491-1495 (2007).
41. Jones, M. E., McInnes, K. J., Boon, w. C. & simpson, E. R. Estrogen and adiposity-utilizing models of aromatase deficiency to explore the relationship. J. Steroid Biochem. Mol. Biol. 106, 3-7 (2007).
42. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and â-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985).
43. Neuschwander-Tetri, B. A. & Caldwell, s. H. Nonalcoholic steatohepatitis: summary of an AAsLD single Topic Conference. Hepatology 37, 1202-1219 (2003).
44. Lonardo, A., Carani, C., Carulli, N. & Loria, P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J. Hepatol. 44, 1196-1207 (2006).
45. Bilezikian, J. P., Morishima, A., Bell, J. & Grumbach, M. M. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 339, 599-603 (1998).
46. Rochira, V. et al. Pituitary function in a man with congenital aromatase deficiency: effect of different doses of transdermal E2 on basal and stimulated pituitary hormones. J. Clin. Endocrinol. Metab. 87, 2857-2862 (2002).
47. Zimmet, P., Magliano, D., Matsuzawa, Y., Alberti, G. & shaw, J. The metabolic syndrome: a global public health problem and a new definition. J. Atheroscler. Thromb. 12, 295-300 (2005).
48. van den Bosch, J. s., smals, A. G., Pieters, G. F., Valk, I. M. & Kloppenborg, P. w. Instant growth inhibition by low dose estrogens in excessively tall boys. Acta Endocrinol. (Copenh.) 100, 327-332 (1982).
49. Caruso-Nicoletti, M. et al. short term, low dose estradiol accelerates ulnar growth in boys. J. Clin. Endocrinol. Metab. 61, 896-898 (1985).
50. Cutler, G. B. Jr. The role of estrogen in bone growth and maturation during childhood and adolescence. J. Steroid Biochem. Mol. Biol. 61, 141-144 (1997).
51. weise, M. et al. Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc. Natl Acad. Sci. USA 98, 6871-6876 (2001).
52. Rochira, V. et al. sex steroids and body proportions in two men with aromatase deficiency: evidences for a key role of estrogen deficiency on eunuchoid skeleton [abstract]. In 7th European Congress of Endocrinology 270 (2005).
53. Andersson, A. M. et al. serum inhibin B in healthy pubertal and adolescent boys: relation to age, stage of puberty, and follicle-stimulating hormone, luteinizing hormone, testosterone, and estradiol levels. J. Clin. Endocrinol. Metab. 82, 3976-3981 (1997).
54. Rochira, V. et al. skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone. Bone 40, 1662-1668 (2007).
55. Khosla, s., Melton, L. J. 3rd, Atkinson, E. J. & O'Fallon, w. M. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86, 3555-3561 (2001).
56. Herrmann, B. L., Janssen, O. E., Hahn, s., Broecker-Preuss, M. & Mann, K. Effects of estrogen replacement therapy on bone and glucose metabolism in a male with congenital aromatase deficiency. Horm. Metab. Res. 37, 178-183 (2005).
57. Vanderschueren, D., Venken, K., Ophoff, J., Bouillon, R. & Boonen, s. Clinical Review: sex steroids and the periosteum--reconsidering the roles of androgens and estrogens in periosteal expansion. J. Clin. Endocrinol. Metab. 91, 378-382 (2006).
58. Balestrieri, A., Madeo, B., Rochira, V., Baldini, L. & Carani, C. Bilateral osteonecrosis of the femoral head in an adult man affected by congenital estrogen deficiency. J. Endocrinol. Invest. 26, 762-764 (2003).
59. Zirilli, L. et al. The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency. Bone doi:10.1016/j.bone.2009.03.672.).
60. Carani, C., Rochira, V., Faustini-Fustini, M., Balestrieri, A. & Granata, A. R. Role of estrogen in male sexual behavior: insights from the natural model of aromatase deficiency. Clin. Endocrinol. (Oxf.) 51, 517-524 (1999).
61. Carani, C. et al. sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadism. Psychoneuroendocrinology 30, 413-417 (2005).
62. sudhir, K. & Komesaroff, P. A. Clinical review 110: Cardiovascular actions of estrogens in men. J. Clin. Endocrinol. Metab. 84, 3411-3415 (1999).
63. Mendelsohn, M. E. & Karas, R. H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340, 1801-1811 (1999).
64. Pitteloud, N. et al. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J. Clin. Endocrinol. Metab. 93, 784-791 (2008).
65. smith, E. P. et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J. Clin. Endocrinol. Metab. 93, 3088-3096 (2008).
66. Mitamura, R. et al. Diurnal rhythms of luteinizing hormone, follicle-stimulating hormone, and testosterone secretion before the onset of male puberty. J. Clin. Endocrinol. Metab. 84, 29-37 (1999).
67. Vottero, A. et al. Aromatase is differentially expressed in peripheral blood leukocytes from children, and adult female and male subjects. Eur. J. Endocrinol. 154, 425-431 (2006).
68. Pepe, C. M. et al. The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues. Clin. Endocrinol. (Oxf.) 67, 698-705 (2007).
69. Pandey, A. V., Kempná, P., Hofer, G., Mullis, P. E. & Flück, C. E. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol. Endocrinol. 21, 2579-2595 (2007).
70. Choi, B. G. & McLaughlin, M. A. why men's hearts break: cardiovascular effects of sex steroids. Endocrinol. Metab. Clin. North Am. 36, 365-377 (2007).